MMP9 and metabolic syndrome: Other studies have demonstrated that in obese subjects with metabolic syndrome and hypertension endothelial dysfunction may be predicted by the ratio between matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases (TIMPs) [65].